Connect to share and comment

Novartis loses landmark India patent case on Glivec

India's top court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.The decision sets a benchmark for intellectual property cases in India, where many patented drugs are unaffordable for most of its 1.2 billion people, and does not bode well for foreign firms engaged in ongoing disputes in India, including Pfizer Inc and Roche Holding AG, analysts said.

India hails "historic" Supreme Court drug patent ruling against Novartis

NEW DELHI (Reuters) - The Indian government hailed as "historic" a Supreme Court ruling on Monday against a plea by Swiss drugmaker Novartis AG to protect the patent on its drug Glivec. Commerce and Industry Minister Anand Sharma said the ruling -- seen as a victory by health rights campaigners -- reaffirmed provisions in Indian law that mandate the need for substantial innovation before new patents are issued on medicines. (Reporting By Matthias Williams; Writing by Frank Jack Daniel, editing by Ross Colvin)

Novartis India will continue to file for patents - executive

MUMBAI (Reuters) - Novartis India Ltd, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec. Novartis India will also continue to invest there, but with caution, Ranjit Shahani, who is also the managing director of the company, told reporters after the Supreme Court judgment.

URGENT ¥¥¥ Novartis condemns India patent ruling

Swiss drugs giant Novartis condemned on Monday the Indian Supreme Court's dismissal of its patent bid for a blockbuster cancer drug, saying it "discourages future innovation". Novartis said in a statement the decision, which capped a seven-year legal battle to gain patent protection for an updated version of leukemia drug Glivec, "discourages innovative drug discovery essential to advancing medical science for patients". pmc/rob/jms

Novartis loses Indian patent fight in landmark ruling

India's top court denied Monday a patent request by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic versions of drugs in developing nations. The Supreme Court ruled that the compound for a new version of its blockbuster cancer drug Glivec, for which Novartis was seeking a patent, "did not satisfy the test of novelty or inventiveness" required by Indian law. The judgement capped a seven-year legal battle by Novartis to win protection for the drug that went to the heart of India's patent law.

URGENT ¥¥¥ Novartis loses Indian patent fight in landmark ruling

India's top court denied Monday a patent request by Swiss drug giant Novartis for its cancer drug Glivec in a landmark decision seen as crucial for India's status as a global source of cheap medicines. The Supreme Court ruled that the compound for which Novartis was seeking a patent "did not satisfy the test of novelty or inventiveness" required by Indian law. str-pmc/adp/pj

Novartis loses landmark India cancer drug patent case

By Kaustubh Kulkarni and Suchitra Mohanty MUMBAI/NEW DELHI (Reuters) - India's top court dismissed Swiss drug maker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.
Syndicate content